Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 15 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 8829024

    Combination steroid and glucocorticoid receptor antagonist therapy

    Corcept Therapeutics Incorporated · Granted Sep 9, 2014 · Expires Sep 4, 2034

    granted

  2. US 8815917

    DP2 antagonist and uses thereof

    Panmira Pharmaceuticals, LLC · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted

  3. US 8815907

    Quaternary ammonium compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted

  4. US 8816088

    Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Aug 26, 2014 · Expires Aug 21, 2034

    granted

  5. US 8802107

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  6. US 8802856

    Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  7. US 8802698

    8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Aug 12, 2014 · Expires Aug 7, 2034

    granted

  8. US 8796291

    A3 adenosine receptor antagonists and partial agonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 5, 2014 · Expires Jul 31, 2034

    granted

  9. US 8785393

    Ophthalmic pharmaceutical compositions of DP2 receptor antagonists

    Panmira Pharmaceuticals, LLC · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  10. US 8785442

    Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof

    Curegenix, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  11. US 8785633

    Guanidine-containing compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted

  12. US 8778983

    Polycyclic compounds as lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Jul 15, 2014 · Expires Jul 10, 2034

    granted

  13. US 8772331

    Small molecule antagonists of bacterial quorum-sensing receptors

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jul 8, 2014 · Expires Jul 3, 2034

    granted

  14. US 8765125

    Methods of treating autoimmune diseases with Dll4 antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2014 · Expires Jun 26, 2034

    granted

  15. US 8722896

    Prokineticin receptor antagonists and uses thereof

    The Regents of the University of California · Granted May 13, 2014 · Expires May 8, 2034

    granted

  16. US 8710004

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 29, 2014 · Expires Apr 24, 2034

    granted

  17. US 8703791

    3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Apr 22, 2014 · Expires Apr 17, 2034

    granted

  18. US 8703730

    Complement antagonists and uses thereof

    REGENESANCE B.V. · Granted Apr 22, 2014 · Expires Apr 17, 2034

    granted

  19. US 8680132

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 25, 2014 · Expires Mar 20, 2034

    granted

  20. US 8680131

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Mar 25, 2014 · Expires Mar 20, 2034

    granted

  21. US 8664220

    Polycyclic compounds as lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted

  22. US 8664242

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance, Inc. · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted

  23. US 8648072

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Feb 11, 2014 · Expires Feb 6, 2034

    granted

  24. US 8636997

    Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Jan 28, 2014 · Expires Jan 23, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.